| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wei-Jia Li, Paraschos Archontakis-Barakakis, Leonidas Palaiodimos, Dimitrios Kalaitzoglou, Lazaros Tzelves, Apostolos Manolopoulos, Yu-Chiang Wang, Stefanos Giannopoulos, Robert Faillace and Damianos G Kokkinidis |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Damianos G Kokkinidis, MD, MSc, Academic Fellow, Doctor, Doctor, Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, United States. damiankokki@gmail.com |
| Key Words |
Novel oral anticoagulant; Direct oral anticoagulant; Atrial fibrillation; Asian population; Dabigatran; Rivaroxaban; Apixaban; Warfarin |
| Core Tip |
Dabigatran, rivaroxaban, apixaban have better efficacy (reduction in ischemic stroke and all-cause mortality) and are safer (reduction in major bleeding) than warfarin. Dabigatran is associated with a lower rate of intracranial hemorrhage than warfarin, while rivaroxaban and apixaban appear to have a trend towards reduced intracranial hemorrhage, without statistical significance. Dabigatran, rivaroxaban, and apixaban are associated with a lower rate of gastrointestinal bleeding. |
| Publish Date |
2021-04-21 09:34 |
| Citation |
Li WJ, Archontakis-Barakakis P, Palaiodimos L, Kalaitzoglou D, Tzelves L, Manolopoulos A, Wang YC, Giannopoulos S, Faillace R, Kokkinidis DG. Dabigatran, rivaroxaban, and apixaban compared to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis. World J Cardiol 2021; 13(4): 82-94 |
| URL |
https://www.wjgnet.com/1949-8462/full/v13/i4/82.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v13.i4.82 |
